Royalty Pharma

📍 New York, United States🗓 Founded 1996👥 97 employees💰 Last funded Mar 2021
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
1996
Founded
Investor geography2 countries
Switzerland
1
United States
1
Frequently asked questions
Who invested in Royalty Pharma?
Royalty Pharma has 2 investors on record on gritt.io, including 1 early-stage backers.
When did Royalty Pharma last raise funding?
The most recent investment in Royalty Pharma recorded on gritt.io was in March 2021.
When was Royalty Pharma founded?
Royalty Pharma was founded in 1996.
What industry is Royalty Pharma in?
Royalty Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Royalty Pharma based?
Royalty Pharma is headquartered in New York, United States.